Phase II clinical trial - Recherches "plusieurs pathologies"

This is a Prospective Randomized Open Blinded Endpoint phase II clinical trial. The study will be adaptive: an interim analysis is planned after enrolment of 20 patients in each arm of treatment (WBRT and AGuIX« + WBRT), to select and continue the study with group(s) that present the best response rate to the experimental treatment (AGuIX« + WBRT).;The main endpoint will be evaluated by a blinded endpoint committee.